Why the study?
The study was designed to examine the association of C-reactive protein to albumin ratio with short-term major adverse cardiac events in STEMI patients undergoing pPCI.
Does the C-reactive protein to albumin ratio (CAR) predict short-term major adverse cardiac events in STEMI patients undergoing primary PCI?
Does the C-reactive protein to albumin ratio (CAR) predict short-term major adverse cardiac events in STEMI patients undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
The C-reactive protein to albumin ratio is an independent predictor of short-term MACE in STEMI patients undergoing primary PCI, suggesting its utility for risk stratification.
The present study aimed to examine the association of C-reactive protein to albumin ratio (CAR) with short-term major adverse cardiac events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI). We included 539 STEMI patient treated with pPCI in this study. Patients were divided into 2 groups according to MACE development. Patients with MACE had higher CAR than those without (1.18 [0.29-1.99] vs 0.21 [0.09-0.49], P < .001). Multivariate analysis showed that The Global Record for Acute Coronary Events score, Percutaneous Coronary Intervention with TAXus and cardiac surgery (SYNTAX) score, glucose and CAR (odds ratio:1.326, 95% CI: 1.212-1452, P < .001) were independent predictors of MACE. The CAR may be proven useful for risk stratification in STEMI patients undergoing pPCI.
No takes yet. Share an insight, caveat, or question.
Acet et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: